

DAFTAR PUSTAKA

1. Sutnick AI, Gunawan S. Cancer in Indonesia. Globocan 2020. 2021;360 indonesia.
2. Putriyuni A, Oktora MZ, Nurwiyeni N, Tofrizal T. Potential Forkhead Box O 3a as Prognostic Biomarker in Prostate Cancer. Proc 1st Int Conf Heal Sci Biotechnol (ICHB 2021). 2022;47(Ichb 2021):19–23.
3. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, *et al*. Prostate cancer. Nat Rev Dis Prim [Internet]. 2021;7(1). Available from: <http://dx.doi.org/10.1038/s41572-020-00243-0>
4. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–80.
5. Netto GJ, Amin MB, Kench JG. Tumor of the prostate. in: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours [Internet]. 5th ed. Lyon (France): International Agency for Research on Cancer (IARC); 2022. Available from: <https://tumourclassification.iarc.who.int/chapters/36>.
6. Wu Z, Shi J, Lai C, Li K, Li K, Li Z, *et al*. Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients. Urol Oncol Semin Orig Investig [Internet]. 2021;39(7):433.e17-433.e23. Available from: <https://doi.org/10.1016/j.urolonc.2021.05.004>
7. Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther [Internet]. 2021;228:107932. Available from: <https://doi.org/10.1016/j.pharmthera.2021.107932>
8. Owen JS, Clayton A, Pearson HB. Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer. Biomolecules. 2023;13(1):1–45.
9. Boudadi K, Antonarakis ES. Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2016;10:1–9.

10. Bonollo F, Thalmann GN, Julio MK De, Karkampouna S. The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. *Cancers (Basel)*. 2020;12(7):1–28.
11. Krušlin B, Ulamec M, Tomas D. Prostate cancer stroma: An important factor in cancer growth and progression. *Bosn J Basic Med Sci*. 2015;15(2).
12. Humphrey PA. Histopathology of prostate cancer. *Cold Spring Harb Perspect Med*. 2017;7(10):1–22.
13. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: Cancer-associated fibroblasts and their markers. *Int J Cancer*. 2020;146(4):895–905.
14. San Martin R, Barron DA, Tuxhorn JA, Ressler SJ, Hayward SW, Shen X, *et al*. Recruitment of CD34+ fibroblasts in tumor-associated reactive stroma: The reactive microvasculature hypothesis. *Am J Pathol* [Internet]. 2014;184(6):1860–70. Available from: <http://dx.doi.org/10.1016/j.ajpath.2014.02.021>
15. Clark KC, Wu Y, Taylor RA, Daly RJ. Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs). *Crit Rev Oncog*. 2022;27(1):1–24.
16. Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. *Semin Cancer Biol* [Internet]. 2014;25:61–8. Available from: <http://dx.doi.org/10.1016/j.semcancer.2014.02.006>
17. Hoeh B, Wenzel M, Hohenhorst L, Köllermann J, Graefen M, Haese A, *et al*. Anatomical Fundamentals and Current Surgical Knowledge of Prostate Anatomy Related to Functional and Oncological Outcomes for Robotic-Assisted Radical Prostatectomy. *Front Surg*. 2022;8(February):1–10.
18. Bashir MN. Epidemiology of prostate cancer. *Asian Pacific J Cancer Prev*. 2015;16(13):5137–41.
19. Rawla P. Epidemiology of Prostate Cancer. *World J Oncol*. 2019;10(2):63–89.
20. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. *Cold Spring Harb Perspect Med*. 2018;8(12).

21. Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. *Jpn J Clin Oncol*. 2015;45(8):708–12.
22. Ha Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men. *Prostate Int* [Internet]. 2019;7(1):1–8. Available from: <https://doi.org/10.1016/j.pnil.2018.11.001>
23. Murray TBJ. The Pathogenesis of Prostate Cancer. *Prostate Cancer*. 2021;29–42.
24. Karpisheh V, Mousavi SM, Naghavi Sheykholeslami P, Fathi M, Mohammadpour Saray M, Aghebati-Maleki L, *et al*. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. *Life Sci* [Internet]. 2021;284(December 2020):119132. Available from: <https://doi.org/10.1016/j.lfs.2021.119132>
25. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: An important clinical entity. *Nat Rev Urol* [Internet]. 2014;11(6):317–23. Available from: <http://dx.doi.org/10.1038/nrurol.2014.91>
26. Patil N, Gaitonde K. Clinical perspective of prostate cancer. *Top Magn Reson Imaging*. 2016;25(3):103–8.
27. Lindh C, Delahunt B, Egevad L. Macroscopic features of prostate cancer. *Pathology*. 2018;50(4):382–8.
28. Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, *et al*. The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer. *Arch Pathol Lab Med*. 2021;145(4):461–93.
29. Varma M. An update on atypical large glandular proliferations of the prostate. *Diagnostic Histopathol* [Internet]. 2023; Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617313220>
30. Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, *et al*. Prostate cancer: From Gleason scoring to prognostic grade grouping. *Expert Rev Anticancer Ther*. 2016;16(4):433–40.

31. van Leenders GJLH, Verhoef EI, Hollemans E. Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. Vol. 77, Histopathology. 2020. p. 850–61.
32. Linkon AHM, Labib MM, Hasan T, Hossain M, Jannat ME. Deep learning in prostate cancer diagnosis and Gleason grading in histopathology images: An extensive study. Informatics Med Unlocked [Internet]. 2021;24(April):100582. Available from: <https://doi.org/10.1016/j.imu.2021.100582>
33. Zhou M, Magi-Galluzzi C. Genitourinary Pathology. 2nd ed. Philadelphia: Elsevier Inc.; 2015. 69–137 p.
34. Grizzle WE, Kittles RA, Rais-Bahrami S, Shah E, Adams GW, DeGuenther MS, *et al.* Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy. Cancer Med. 2019;8(16):6915–22.
35. Clark R, Vesprini D, Narod SA. The Effect of Age on Prostate Cancer Survival. Cancers (Basel). 2022;14(17):1–12.
36. Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, *et al.* Prognostic features of Annexin A2 expression in prostate cancer. Pathology. 2021;53(2):205–13.
37. Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M. “Stromal cells in prostate cancer pathobiology: friends or foes?” Br J Cancer. 2022;(October).
38. ChallaSivaKanaka S, Vickman RE, Kakarla M, Hayward SW, Franco OE. Fibroblast heterogeneity in prostate carcinogenesis. Cancer Lett. 2022;525:76–83.
39. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, *et al.* A framework for advancing our understanding of cancer-associated fibroblasts [Internet]. Vol. 20, Nature Reviews Cancer. Springer US; 2020. p. 174–86. Available from: <http://dx.doi.org/10.1038/s41568-019-0238-1>
40. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov [Internet]. 2019;18(2):99–115. Available from: <http://dx.doi.org/10.1038/s41573-018-0004-1>

41. Levesque C, Nelson PS. Cellular constituents of the prostate stroma: Key contributors to prostate cancer progression and therapy resistance. *Cold Spring Harb Perspect Med*. 2018;8(8):1–16.
42. Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. *J Clin Med*. 2016;5(2).
43. Taddei ML, Cavallini L, Ramazzotti M, Comito G, Pietrovito L, Morandi A, *et al*. Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy. *J Cell Physiol*. 2019;234(6):8274–85.
44. Odero-Marrah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-mesenchymal transition (EMT) and prostate cancer. *Adv Exp Med Biol*. 2018;1095:101–10.
45. Choi KJ, Nam JK, Kim JH, Choi SH, Lee YJ. Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage. *Exp Mol Med* [Internet]. 2020;52(5):781–92. Available from: <http://dx.doi.org/10.1038/s12276-020-0439-4>
46. Wen S, Niu Y, Yeh S, Chang C. BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. *Int J Oncol*. 2015;47(2):719–27.
47. Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, *et al*. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. *Prostate*. 2020;80(2):173–85.
48. Pan J, Ma Z, Liu B, Qian H, Shao X, Liu J, *et al*. Identification of cancer-associated fibroblasts subtypes in prostate cancer. *Front Immunol*. 2023;14(March):1–15.
49. Chougani S, GV S, Kharidehal D, V R, Vissa S. Utility of PIN4 cocktail antibody in the atypical foci of the Prostate. *Int J Clin Diagnostic Pathol*. 2020;3(1):396–403.
50. Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. *Clin Cancer Res*. 2020;26(18):4882–91.

51. Pellinen T, Sandeman K, Blom S, Turkki R, Hemmes A, Välimäki K, *et al.* Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. *Cancer Res Commun.* 2022;2(3):172–81.
52. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, *et al.* Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. *J Nucl Med.* 2022;63(7):1021–6.
53. Wikström P, Bergström SH, Josefsson A, Semenas J, Nordstrand A, Thysell E, *et al.* Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy. *Cancers (Basel).* 2022;14(21).
54. Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K. The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment. *Cancer Sci.* 2023;114(1):16–24.
55. Ketteler J, Panic A, Reis H, Wittka A, Maier P, Herskind C, *et al.* Progression-related loss of stromal caveolin 1 levels mediates radiation resistance in prostate carcinoma via the apoptosis inhibitor TRIAP1. *J Clin Med.* 2019;8(3).
56. Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, *et al.* Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. *Ann Nucl Med [Internet].* 2022;36(3):293–301. Available from: <https://doi.org/10.1007/s12149-021-01702-8>
57. Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, *et al.* High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. *Eur J Nucl Med Mol Imaging [Internet].* 2021;49(1):385–9. Available from: <https://doi.org/10.1007/s00259-021-05423-y>
58. Eiro N, Fernández-Gómez JM, de León CGR, Fraile M, Gonzalez-Suarez J, Lobo-Rodríguez B, *et al.* Gene Expression Profile of Stromal Factors in Cancer-Associated Fibroblasts from Prostate Cancer. *Diagnostics.*

2022;12(7):1–15.

59. Tolkach Y, Kristiansen G. The Heterogeneity of Prostate Cancer: A Practical Approach. *Pathobiology*. 2018;85(1–2):108–16.
60. Putriyuni A, Hilbertina N. Adenokarsinoma Prostat: Penilaian Prognostik Dan Derajat Histopatologi. *Maj Kedokt Andalas*. 2015;37(2):93.
61. Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. *Sci Rep* [Internet]. 2020;10(1):1–6. Available from: <https://doi.org/10.1038/s41598-020-76786-9>
62. Rizky Prasetya G, Saraswati M, Rizal AH, Hamid A, BRE. Matondang S. Clinicopathological Profile of Prostate Adenocarcinoma Cases at Cipto Mangunkusumo Hospital in 2010-2019 with Special Overview of Robotic Biopsy. *Maj Patol Indones*. 2022;31(3):462–70.
63. Murtiyani S, S. Hernowo B, Suryanti S. Hubungan CXC Chemokine Receptor 4 (CXCR4) dan Matrix Metalloproteinase 9 (MMP 9) dengan Kemampuan Metastasis Adenokarsinoma Prostat. *J Kedokt Yars*. 2019;27(1):024–34.
64. Nurlaili R, Apriyani N, Saleh MI. Ekspresi alpha methylacyl co-a racemase (amacr) pada adenokarsinoma prostat dan high grade prostatic intraepithelial neoplasia (hgpin). *J Kedokt dan ...* [Internet]. 2017;4(2):76–82. Available from: <https://jkk-fk.ejournal.unsri.ac.id/index.php/jkk/article/download/82/82>
65. Oktavia R. Profil Histopatologik Adenokarsinoma Prostat di La. 2017;9(Supplement 1):99–106.
66. Myint ZW, Sun RC, Hensley PJ, James AC, Wang P, Strup SE, *et al*. Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters. *Cancers (Basel)*. 2021;13(9).
67. Prendeville S, Nesbitt ME, Evans AJ, Fleshner NE, van der Kwast TH. Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy. *J Urol* [Internet]. 2017;198(1):79–85. Available from: <http://dx.doi.org/10.1016/j.juro.2017.01.061>

68. Kryvenko ON, Williamson SR, Schwartz LE, Epstein JI. Gleason score $5 + 3 = 8$ (grade group 4) prostate cancer—a rare occurrence with contemporary grading. *Hum Pathol* [Internet]. 2020;97:40–51. Available from: <https://doi.org/10.1016/j.humpath.2019.11.002>
69. Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico A V. Gleason Score $3 + 5$ or $5 + 3$ versus $4 + 4$ Prostate Cancer: The Risk of Death. *Eur Urol* [Internet]. 2016;69(6):976–9. Available from: <http://dx.doi.org/10.1016/j.eururo.2015.08.054>
70. Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, *et al.* Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. *Clin Genitourin Cancer* [Internet]. 2019;17(3):231-237.e2. Available from: <https://doi.org/10.1016/j.clgc.2019.04.009>
71. Ortiz-Otero N, Clinch AB, Hope J, Wang W, Reinhart-King CA, King MR. Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. *Oncotarget*. 2020;11(12):1037–50.
72. Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival. *Genes (Basel)*. 2022;13(1).
73. Gerashchenko G V., Grygoruk O V., Kononenko OA, Gryzodub OP, Stakhovsky EO, Kashuba VI. Expression pattern of genes associated with tumor microenvironment in prostate cancer. *Exp Oncol*. 2018;40(4):315–22.
74. Hesterberg AB, Rios BL, Wolf EM, Tubbs C, Wong HY, Schaffer KR, *et al.* A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer. *J Pathol Clin Res*. 2021;7(3):271–86.
75. Gevaert T, Van Eycke YR, Vanden Broeck T, Van Poppel H, Salmon I, Rorive S, *et al.* Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. *Sci Rep*. 2018;8(1):1–12.

76. Dmochowska N, Milanova V, Mukkamala R, Chow KK, Pham NTH, Srinivasarao M, *et al.* Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. *Small*. 2023;19(21):1–28.

